BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Centre de Recherches en Cancérologie de Toulouse - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Centre de Recherches en Cancérologie de Toulouse
X-ORIGINAL-URL:https://www.crct-inserm.fr
X-WR-CALDESC:Évènements pour Centre de Recherches en Cancérologie de Toulouse
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20251208T110000
DTEND;TZID=Europe/Paris:20251208T120000
DTSTAMP:20260408T081242
CREATED:20251125T152853Z
LAST-MODIFIED:20251201T095800Z
UID:62891-1765191600-1765195200@www.crct-inserm.fr
SUMMARY:Conférence Dr Robert Ballotti - Identifying the Epigenetic Players Involved in Melanoma Resistance to Targeted Therapies and to the Immune System.
DESCRIPTION:Identifying the Epigenetic Players Involved in Melanoma Resistance to Targeted Therapies and to the Immune System. \nSince 2011-2012 and the use of targeted therapies and immunotherapies in the treatment of metastatic melanoma\, progress in terms of patient survival is evident\, with an increase in median survival from less than a year to over 5 years with immunotherapies. However\, almost 50% of patients are in therapeutic dead-end\, due to frequent resistance to treatment.  The main challenge today is to decipher the mechanisms of resistance to targeted therapies (TC) or immunotherapies (IT) and propose therapeutic approaches to block or reverse these processes. \nIn 2018\, we demonstrated that increased cellular levels of NAD+ render melanoma cells resistant to targeted therapies. This resistance is associated with dedifferentiation and specific epigenetic modifications. Focusing on these non-genetic resistance patterns associated with dedifferentiation\, we have identified epigenetic players whose inhibition resensitizes melanoma cells to TCs and increases their immunogenicity. \nOur data identify epigenetic players involved in the acquisition of resistance to TC and in the alteration of the immune response in melanoma cells. This results lay the foundations for new therapeutic strategies targeting epigenetic alterations to overcome resistance. \nPour suivre la conférence à distance\, cliquez ici.
URL:https://www.crct-inserm.fr/evenement/conference-dr-robert-ballotti-identifying-the-epigenetic-players-involved-in-melanoma-resistance-to-targeted-therapies-and-to-the-immune-system/
LOCATION:Salle Cazaux
CATEGORIES:Animation scientifique
ATTACH;FMTTYPE=image/png:https://www.crct-inserm.fr/wp-content/uploads/2025/11/conf-robert-ballotti.png
END:VEVENT
END:VCALENDAR